Key result
Study protocol outlines planned evaluation of beta-blockers and apixaban dosing on thromboembolism without reported results.
Why the study?
Conflicting evidence exists regarding whether apixaban underdosing in nonvalvular AF maintains efficacy against stroke/systemic embolism while reducing bleeding, or increases thromboembolism risk without safety benefits.
Observational
Discretionary apixaban underdosing should not yet change practice; leaves open true equivalence given residual confounding.
Background: Apixaban, a direct oral anticoagulant (DOAC), is widely used for stroke prevention in patients with nonvalvular atrial fibrillation (AF). Its dose is adjusted based on age, body weight and renal function; however, even when patients meet criteria for the standard dose, physicians may prescribe a reduced dose at their discretion (underdosing). Previous studies have reported comparable risk of stroke/systemic embolism between patients receiving the standard-dose (5 mg twice daily) and those receiving an under-dose (2.5 mg twice daily), whereas bleeding risk was lower in the latter. Conversely, another report suggested that under-dosing of DOACs increases thromboembolism risk without reducing bleeding risk. Therefore, this study aimed to evaluate whether thromboembolic risk differs between standard-dose and under-dose apixaban, and to explore the influence of concomitant medications and patient characteristics on these outcomes.
No takes yet. Share an insight, caveat, or question.
Iwane et al. (2026) conducted an observational in Nonvalvular atrial fibrillation. Beta-blockers and under-dose apixaban was evaluated on Thromboembolism. The abstract provides only the background and aims of the study, without reporting any quantitative results regarding the impact of beta-blockers or apixaban dosing on thromboembolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: